Background: The outbreak of novel coronavirus disease (COVID-19) has brought serious psychological pressure to people, especially medical health staff. At present, there are few studies on insomnia and related factors of medical health staff in the middle and late stage of the epidemic of COVID-19. Therefore, the purpose of this study was to investigate the prevalence of insomnia and its related risk factors among medical workers in China in the middle and later stage of COVID-19 epidemic, as well as the relationship between insomnia and psychological resilience.Methods: From February 14 to March 29, 2020, a cross-sectional survey was conducted among 606 medical staff in China through Ranxing Technology's “SurveyStar” network platform. All subjects were assessed with the Insomnia Severity Index (ISI) and simplified Chinese version of Connor-Davidson Resilience scale (CD-RISC-10).Results: In the middle and later stages of the COVID-19 outbreak, the incidence of insomnia among medical staff was 32.0%. Compared with non-insomnia group, the insomnia group had younger age, lower education level, longer daily working hours and less psychological resilience. In addition, the prevalence of insomnia was higher in medical staff with a history of somatic diseases. The severity of insomnia of Chinese medical staff was associated with age, education level, daily working hours, psychological resilience and somatic diseases.Conclusions: Our study shows that nearly 1/3 of Chinese medical workers suffer from insomnia nearly a month after the COVID-19 outbreak. Compared with the general population, medical staff who are working with COVID are more prone to insomnia. Risk factors for insomnia include younger age, lower education level, longer working hours per day, and physical illness. The tenacious dimension of psychological resilience is a protective factor for insomnia.
Objective
Insomnia is the most common complaint in adolescents with mood disorders (MD). However, the psychopathological mechanisms associated with insomnia remain unclear. Therefore, we aimed to explore anxiety’s mediating role in the effect of rumination on insomnia in MD adolescents.
Methods
A total of 569 MD patients were recruited. Participants completed the Patient Health Questionnaire-9 (PHQ-9), 7-item Generalized Anxiety Disorder (GAD-7) scale, and Insomnia Severity Index (ISI) to self-assess their mood and insomnia symptoms. In addition, the 21-item Chinese version of the Ruminative Response Scale (RRS) was used to assess rumination specifically.
Results
The prevalence of insomnia in MD patients was 60.63%, with a higher prevalence in females (63.32%) vs. male patients(54.39%). MD patients with insomnia symptoms also scored higher on depression and anxiety symptom scales, as well as rumination, when compared to MD patients without insomnia. Depression-related rumination and anxiety were correlated with insomnia in MD patients. The AUCROC showed that the combination of depression-related rumination and anxiety could effectively distinguish patients with and without insomnia in MD adolescents. Furthermore, in adolescents with MD, depression-related rumination positively predicted anxiety and insomnia, and anxiety positively predicted insomnia. Finally, anxiety partially mediated the association between depression-related rumination and insomnia.
Conclusion
Our results suggest that depression-related rumination and anxiety are key riskfactors for insomnia in adolescents with MD. Furthermore, anxiety can exacerbate the effects of depression-related rumination on insomnia, suggesting that clinical interventions to reduce depression-related rumination and anxiety may be a viable consideration for insomnia in adolescents with MD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.